Evoke Pharma (NASDAQ: EVOK) and CoLucid Pharmaceuticals (NASDAQ:CLCD) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, risk, earnings, valuation, profitability, analyst recommendations and dividends.

Analyst Ratings

This is a summary of recent ratings and target prices for Evoke Pharma and CoLucid Pharmaceuticals, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Evoke Pharma 0 1 6 0 2.86
CoLucid Pharmaceuticals 0 3 1 0 2.25

Evoke Pharma presently has a consensus price target of $8.86, indicating a potential upside of 202.29%. CoLucid Pharmaceuticals has a consensus price target of $47.83, indicating a potential upside of 2.80%. Given Evoke Pharma’s stronger consensus rating and higher possible upside, analysts plainly believe Evoke Pharma is more favorable than CoLucid Pharmaceuticals.

Profitability

This table compares Evoke Pharma and CoLucid Pharmaceuticals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Evoke Pharma N/A -167.16% -80.56%
CoLucid Pharmaceuticals N/A -83.51% -70.62%

Earnings and Valuation

This table compares Evoke Pharma and CoLucid Pharmaceuticals’ gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Evoke Pharma N/A N/A N/A ($0.97) -3.02
CoLucid Pharmaceuticals N/A N/A N/A ($3.44) -13.53

CoLucid Pharmaceuticals is trading at a lower price-to-earnings ratio than Evoke Pharma, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

12.9% of Evoke Pharma shares are held by institutional investors. Comparatively, 64.2% of CoLucid Pharmaceuticals shares are held by institutional investors. 20.0% of Evoke Pharma shares are held by company insiders. Comparatively, 13.7% of CoLucid Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Risk and Volatility

Evoke Pharma has a beta of 1.19, meaning that its share price is 19% more volatile than the S&P 500. Comparatively, CoLucid Pharmaceuticals has a beta of 1.51, meaning that its share price is 51% more volatile than the S&P 500.

Summary

Evoke Pharma beats CoLucid Pharmaceuticals on 5 of the 9 factors compared between the two stocks.

About Evoke Pharma

Evoke Pharma, Inc. is a specialty pharmaceutical company. The Company is focused primarily on the development of drugs to treat gastrointestinal (GI) disorders and diseases. The Company is developing EVK-001, a metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women. EVK-001 is a formulation of Metoclopramide drug, designed to provide systemic delivery of metoclopramide through intranasal administration. The Company has evaluated EVK-001 in a multicenter, randomized, double-blind, placebo-controlled parallel group, dose-ranging Phase IIb clinical trial. The Company has commenced a Phase III clinical trial of EVK-001 in female patients with symptoms associated with acute and recurrent diabetic gastroparesis. The Phase III clinical trial is a multicenter, randomized, double-blind, placebo-controlled, parallel-group study evaluating the efficacy, safety and population pharmacokinetics of EVK-001 in adult females.

About CoLucid Pharmaceuticals

CoLucid Pharmaceuticals, Inc. is a Phase III clinical-stage biopharmaceutical company. The Company is engaged in developing a small molecule for the acute treatment of migraine headaches. Its product candidates address the needs of migraine patients, including those with cardiovascular risk factors or stable cardiovascular disease and those dissatisfied with existing therapies. Lasmiditan, the Company’s lead product candidate, is an oral tablet for the acute treatment of migraine in adults. Lasmiditan selectively targets 5-HT1F receptors expressed in the trigeminal pathway in the central nervous system (CNS). Lasmiditan is designed to penetrate the CNS and block the pathway that contributes to headache pain. It is developing IV lasmiditan for the acute treatment of headache pain associated with migraine in adults, to be used in emergency rooms and urgent care settings. The Company is conducting its Phase III randomized, double-blind, placebo-controlled clinical trial of lasmiditan.

Receive News & Ratings for Evoke Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evoke Pharma Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.